147 related articles for article (PubMed ID: 6107768)
1. Safety and patient acceptability of intravenous immune globulin in 10% maltose.
Ochs HD; Buckley RH; Pirofsky B; Fischer SH; Rousell RH; Anderson CJ; Wedgwood RJ
Lancet; 1980 Nov; 2(8205):1158-9. PubMed ID: 6107768
[TBL] [Abstract][Full Text] [Related]
2. Modified immune globulin: its use in the prophylactic treatment of patients with immune deficiency.
Ochs HD; Fischer SH; Wedgwood RJ
J Clin Immunol; 1982 Apr; 2(2 Suppl):22S-30S. PubMed ID: 7045155
[TBL] [Abstract][Full Text] [Related]
3. Safety and toxicity of a new serum immunoglobulin G intravenous preparation, IGIV pH 4.25.
Pirofsky B
Rev Infect Dis; 1986; 8 Suppl 4():S457-63. PubMed ID: 3092311
[TBL] [Abstract][Full Text] [Related]
4. Use of intravenous immune globulin therapy: an overview.
Wordell CJ
DICP; 1991; 25(7-8):805-17. PubMed ID: 1949941
[TBL] [Abstract][Full Text] [Related]
5. Comparison of varicella zoster antibody titers in patients given intravenous immune serum globulin or varicella zoster immune globulin.
Paryani SG; Arvin AM; Koropchak CM; Dobkin MB; Wittek AE; Amylon MD; Budinger MD
J Pediatr; 1984 Aug; 105(2):200-5. PubMed ID: 6086866
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease.
Wasserman RL; Irani AM; Tracy J; Tsoukas C; Stark D; Levy R; Chen J; Sorrells S; Roberts R; Gupta S
Clin Exp Immunol; 2010 Sep; 161(3):518-26. PubMed ID: 20550549
[TBL] [Abstract][Full Text] [Related]
7. Immune globulin intravenous replacement after plasma exchange.
Dau PC
J Clin Apher; 1983; 1(2):104-8. PubMed ID: 6681480
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and tolerability of a new intravenous immunoglobulin preparation, IGIV-C, 10% (Gamunex, 10%).
Ballow M; Berger M; Bonilla FA; Buckley RH; Cunningham-Rundles CH; Fireman P; Kaliner M; Ochs HD; Skoda-Smith S; Sweetser MT; Taki H; Lathia C
Vox Sang; 2003 Apr; 84(3):202-10. PubMed ID: 12670369
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, Safety, and Tolerability of Subcutaneous Immune Globulin Injection (Human), 10 % Caprylate/Chromatography Purified (GAMUNEX®-C) in Pediatric Patients with Primary Immunodeficiency Disease.
Heimall J; Chen J; Church JA; Griffin R; Melamed I; Kleiner GI
J Clin Immunol; 2016 Aug; 36(6):600-9. PubMed ID: 27342758
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy of IGIV-C, 10% (caprylate/chromatography) and IGIV-SD, 10% as replacement therapy in primary immune deficiency. A randomized double-blind trial.
Roifman CM; Schroeder H; Berger M; Sorensen R; Ballow M; Buckley RH; Gewurz A; Korenblat P; Sussman G; Lemm G
Int Immunopharmacol; 2003 Sep; 3(9):1325-33. PubMed ID: 12890430
[TBL] [Abstract][Full Text] [Related]
11. Individual patient variations in the kinetics of intravenous immune globulin administration.
Pirofsky B; Campbell SM; Montanaro A
J Clin Immunol; 1982 Apr; 2(2 Suppl):7S-14S. PubMed ID: 7045157
[TBL] [Abstract][Full Text] [Related]
12. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group.
Pediatrics; 1997 Jan; 99(1):93-9. PubMed ID: 8989345
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency.
Wasserman RL; Melamed I; Stein MR; Gupta S; Puck J; Engl W; Leibl H; McCoy B; Empson VG; Gelmont D; Schiff RI;
J Allergy Clin Immunol; 2012 Oct; 130(4):951-7.e11. PubMed ID: 22846381
[TBL] [Abstract][Full Text] [Related]
14. Safety and tolerability of immune globulin intravenous (human), 10% solution in Japanese subjects with mild to moderate Alzheimer's disease.
Arai H; Ichimiya Y; Shibata N; Nakajima T; Sudoh S; Tokuda T; Sujaku T; Yokokawa S; Hoshii N; Noguchi H; Bille A
Psychogeriatrics; 2014 Sep; 14(3):165-74. PubMed ID: 25186799
[TBL] [Abstract][Full Text] [Related]
15. Immune globulin subcutaneous, human - klhw 20% for primary humoral immunodeficiency: an open-label, Phase III study.
Sleasman JW; Lumry WR; Hussain I; Wedner HJ; Harris JB; Courtney KL; Mondou E; Lin J; Stein MR
Immunotherapy; 2019 Nov; 11(16):1371-1386. PubMed ID: 31621458
[No Abstract] [Full Text] [Related]
16. Availability of immune globulin intravenous for treatment of immune deficient patients--United States, 1997-1998.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 1999 Mar; 48(8):159-62. PubMed ID: 10079062
[TBL] [Abstract][Full Text] [Related]
17. Use of intravenous immune globulin in patients receiving bone marrow transplants.
Winston DJ; Ho WG; Rasmussen LE; Lin CH; Chu HL; Merigan TC; Gale RP
J Clin Immunol; 1982 Apr; 2(2 Suppl):42S-47S. PubMed ID: 6282926
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of high-dose intravenous immune globulin therapy for antibody deficiency syndromes.
Sorensen RU; Polmar SH
Am J Med; 1984 Mar; 76(3A):83-90. PubMed ID: 6424462
[TBL] [Abstract][Full Text] [Related]
19. The interaction of immune serum globulin and immune globulin intravenous with complement.
Bing DH
Mol Immunol; 1983 Aug; 20(8):893-900. PubMed ID: 6604863
[TBL] [Abstract][Full Text] [Related]
20. Non-A non-B hepatitis and the safety of intravenous immune globulin, pH 4.2: a retrospective survey. Preliminary communication.
Rousell RH; Good RA; Pirofsky B; Schiff RI
Vox Sang; 1988; 54(1):6-13. PubMed ID: 3126601
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
